These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31799894)

  • 1. Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
    Wen B; Zhao L; Wang Y; Qiu C; Xu Z; Huang K; Zhu H; Li Z; Li H
    Prep Biochem Biotechnol; 2020; 50(3):252-259. PubMed ID: 31799894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy.
    Xian Z; Ma L; Zhu M; Li G; Gai J; Chang Q; Huang Y; Ju D; Wan Y
    Biochem Biophys Res Commun; 2019 Nov; 519(2):267-273. PubMed ID: 31495493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
    Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
    BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What does PD-L1 positive or negative mean?
    Ribas A; Hu-Lieskovan S
    J Exp Med; 2016 Dec; 213(13):2835-2840. PubMed ID: 27903604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening and production of an affibody inhibiting the interaction of the PD-1/PD-L1 immune checkpoint.
    Jing L; Liu J; Cui D; Li Y; Liu Z; Tao L; Zhao Q; Diao A
    Protein Expr Purif; 2020 Feb; 166():105520. PubMed ID: 31644959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.
    Zhang N; Tu J; Wang X; Chu Q
    Immunotherapy; 2019 Apr; 11(5):429-441. PubMed ID: 30698054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses.
    Silva-Pilipich N; Blanco E; Lozano T; Martisova E; Igea A; Herrador-Cañete G; Ballesteros-Briones MC; Gorraiz M; Sarrión P; González-Sapienza G; Lasarte JJ; Vanrell L; Smerdou C
    Cancer Lett; 2023 May; 561():216139. PubMed ID: 37001752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanobody against PDL1.
    Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
    Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high affinity nanobody against endothelin receptor type B: a new approach to the treatment of melanoma.
    Ji L; Dong C; Fan R; Qi S
    Mol Biol Rep; 2020 Mar; 47(3):2137-2147. PubMed ID: 32080807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel
    Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
    Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.